Home › Hemophilia › New York › New York City
Hemophilia clinical trials in New York City, NY
3 studies for Hemophilia are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RecruitingPhase 1/2
- New York Presbyterian Hospital - Weill-Cornell, New York
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
RecruitingPhase 3
- Cornell University||Joan & Sanford I. Weill Medical College, New York
- Weill Cornell Medical College-New York Presbyterian Hospital, New York
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
- Weill Cornell Medical College - New York Presbyterian Hospital, New York
About Hemophilia
Hemophilia is a rare disorder in which the blood does not clot normally. Usually hemophilia usually occurs in males and is inherited. Learn more.
More about Hemophilia on MedlinePlus
Hemophilia trials in other cities
- Indianapolis, IN9 studies
- Seattle, WA8 studies
- Cedar Rapids, IA7 studies
- Los Angeles, CA6 studies
- Philadelphia, PA6 studies
- Dallas, TX5 studies
- Little Rock, AR5 studies
- San Antonio, TX5 studies
- Sacramento, CA5 studies
- Ann Arbor, MI4 studies
- Orange, CA4 studies
- Tampa, FL4 studies
Other studies in New York City
- Breast Cancer144 studies
- Non-Small Cell Lung Cancer123 studies
- Cancer (all types)105 studies
- Prostate Cancer101 studies
- Metastatic Cancer93 studies
- Colorectal Cancer86 studies
- Ovarian Cancer75 studies
- Lung Cancer60 studies
- Multiple Myeloma59 studies
- Pancreatic Cancer57 studies
- Endometrial Cancer54 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.